This new 3-person IVF technique saved kids from inherited diseases
The technique, which is banned in the U.S., transfers pieces from inside the mother's fertilized egg – its nucleus, plus the nucleus of the father's sperm – into a healthy egg provided by an anonymous donor.
The procedure prevents the transfer of mutated genes from inside the mother's mitochondria – the cells' energy factories – that could cause incurable and potentially fatal disorders.
Mutations in mitochondrial DNA can affect multiple organs, particularly those that require high energy, such as the brain, liver, heart, muscles and kidneys.
One of the eight children is now 2 years old, two are between ages 1 and 2 and five are infants. All were healthy at birth, with blood tests showing no or low levels of mitochondrial gene mutations, the scientists reported in the New England Journal of Medicine. All have made normal developmental progress, they said.
The results "are the culmination of decades of work," not just on the scientific/technical challenges but also in ethical inquiry, public and patient engagement, law-making, drafting and execution of regulations and establishing a system for monitoring and caring for the mothers and infants, reproductive medicine specialist Dr. Andy Greenfield of the University of Oxford, who was not involved in the research, said in a statement.
The researchers' "treasure trove of data" is likely to be the starting point of new avenues of investigation, Greenfield said.
Often during IVF screening procedures, doctors can identify some low-risk eggs with very few mitochondrial gene mutations that are suitable for implantation.
But sometimes all of the eggs' mitochondrial DNA carries mutations. In those cases, using the new technique, the U.K. doctors first fertilize the mother's egg with the father's sperm. Then they remove the fertilized egg's 'pronuclei' – that is, the nuclei of the egg and the sperm, which carry the DNA instructions from both parents for the baby's development, survival and reproduction.
Next, they transfer the egg and sperm nuclei into a donated fertilized egg that has had its pronuclei removed.
The donor egg will now begin to divide and develop with its healthy mitochondria and the nuclear DNA from the mother's egg and the father's sperm.
This process, detailed in a second paper in the journal, 'essentially replaces the faulty mitochondrial DNA (mtDNA) with healthy mtDNA from the donor,' senior researcher Mary Herbert, professor of reproductive biology at Newcastle, said at a press briefing.
Blood levels of mtDNA mutations were 95% to 100% lower in six newborns, and 77% to 88% lower in two others, compared to levels of the same variants in their mothers, the researchers reported in a second paper.
In case you missed it: They spent over $200K to expand their family. Doctors say it's common for LGBTQ+ couples.
"These data indicate that pronuclear transfer was effective in reducing transmission of mtDNA disease," they said.
The procedure was tested in 22 women whose babies were likely to inherit such genes. In addition to the eight women who delivered the children described in this report, another one of the 22 is currently pregnant.
Seven of the eight pregnancies were uneventful; in one case, a pregnant woman had blood tests showing high lipid levels.
There have been no miscarriages.
Noted: Ask for genetic testing. It could save your life.
The authors of the current reports have also tried transplanting the nucleus of a mother's unfertilized egg into a donor egg and then fertilizing the donor egg afterward, but they believe their new approach may more reliably prevent transmission of the genetic disorders.
In 2015, the U.K. became the first country in the world to legalize research into mitochondrial donation treatment in humans.
That same year in the U.S., pronuclear transfer was effectively banned for human use by a congressional appropriations bill that prohibited the Food and Drug Administration from using funds to consider the use of "heritable genetic modification".
Reporting by Nancy Lapid; Editing by Michele Gershberg and Lisa Shumaker
This article originally appeared on USA TODAY: A new 3-person IVF technique saved kids from inherited diseases
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Fresh botulism warning from health chiefs after Botox reactions
Health chiefs have urged people to be aware of the signs and symptoms of botulism after more people suffered reactions following cosmetic procedures involving botulinum toxin, also known as Botox. The new cases: in the east of England and East Midlands; suggest the use of an unlicensed Botox-like product, the UK Health Security Agency (UKHSA) said. They are not thought to be linked to the cases reported in the north east of England last month. Reactions have included severe eyelid drooping, double vision, trouble swallowing, slurred speech and lethargy, which can happen weeks after the procedure. There have been 38 cases of iatrogenic botulism – a rare form of the illness that happens as a result of medical treatment – reported between June 4 and July 14, according to UKHSA data. Dr Gauri Godbole, consultant medical microbiologist at UKHSA, said: 'Botulism related to aesthetic procedures is rare, but it can be serious. 'It is caused by toxins produced by the bacterium clostridium botulinum. 'These toxins, but not the bacteria, are the active ingredient in Botox and similar products. 'Symptoms of botulism can take up to four weeks to develop and if you have had a recent botulinum toxin (Botox-like) treatment and are having symptoms such as difficulty swallowing or breathing, contact NHS 111 for further advice and seek treatment.' Dr Godbole also urged anyone considering having cosmetic procedures to check that their practitioner is licensed. Professor Meghana Pandit, co-national medical director secondary care at NHS England, added: 'When these procedures go wrong, there is a risk of serious infections and permanent scarring, which is why only registered professionals like a doctor, a nurse or pharmacy prescriber should be prescribing these treatments.' Dr Alison Cave, chief safety officer at the Medicines and Healthcare products Regulatory Agency, warned that 'botulinum toxin is a prescription-only medicine and should only be sold or supplied in accordance with a prescription given by an appropriate practitioner such as a doctor or other qualified healthcare professional'. She said: 'Buying botulinum toxin in any other circumstances significantly increases the risk of getting a product which is either falsified or not licensed for use in the UK. 'This means that there are no safeguards to ensure products meet the MHRA's standards for quality and safety. As such, they can endanger the health of the people who take them. 'Our criminal enforcement unit works hard to identify those involved in the illegal trade in medicines and takes robust enforcement action where necessary. This can include criminal prosecution.' The practitioners involved with the latest cases have ceased the procedure and are co-operating with the investigation, the UKHSA said. The agency is advising healthcare staff to ensure they look out for botulism in people who may have had a recent aesthetic procedures. Treatment for the symptoms includes an anti-toxin.
Yahoo
28 minutes ago
- Yahoo
Dad Recalls Thinking His 1-Year-Old Daughter Had Covid Before She Received a Heartbreaking Diagnosis in Emotional Interview
NEED TO KNOW A father in England is recalling thinking his daughter, 15 months, had Covid before she received a heartbreaking diagnosis Terry Archbold revealed on the U.K. show This Morning that his daughter, Bea, experienced "heart failure" and was diagnosed with a heart condition at just 15 months old She's since had a heart transplant after having to wait in the hospital for 14 months for a donor after being fitted with an artificial organA father in England is speaking out about the moment he mistook his daughter's potentially fatal medical condition for Covid. During an appearance on the Friday, July 18 episode of the U.K. show This Morning, police officer Terry Archbold said that his daughter Bea was born "fit" and "healthy" in 2021, before "she suddenly fell ill" and "deteriorated very, very quickly with heart failure" at just 15 months old. Terry shared that the family had been on vacation to Florida, and his partner Cheryl and their other daughter had contracted Covid. So, when Bea fell ill, they assumed she might also have the virus. Terry recalled, "We saw similar symptoms with Bea. Breathless, lethargic," adding that they weren't "overly concerned" at that point, but it "went on for a couple of days." After the infant stopped drinking, her parents sought medical advice, and after an ambulance was sent to the home, they recommended she go to a local emergency room to get checked out. "I expected her to be home in a couple of hours with antibiotics or whatever, never expecting to be told that they picked up a heart murmur, that she was in heart failure," Terry told hosts Dermot O'Leary and Sian Welby. Bea was taken to the Freeman Hospital in the U.K. city of Newcastle upon Tyne, where she was diagnosed with dilated cardiomyopathy, Terry recalled. Per the Mayo Clinic, "Dilated cardiomyopathy is a type of heart muscle disease that causes the heart chambers (ventricles) to thin and stretch, growing larger. It typically starts in the heart's main pumping chamber (left ventricle)." "Dilated cardiomyopathy makes it harder for the heart to pump blood to the rest of the body," the site adds. Little Bea, now 5, ended up having a Hickman line — which is a type of catheter that's fitted to help a patient receive medication, per the Cleveland Clinic — and her parents had then received a phone call to say they could visit their daughter and she was "doing well," Terry shared. However, after they got to the hospital, "We heard alarms and we heard staff shouting for equipment," Terry remembered on the show, adding, "And Cheryl said to me, 'Will you look?' We knew it was Bea, we just knew." He said that medics saved Bea by administering CPR after she went into cardiac arrest, but had then told them, "They said if she had another cardiac arrest, she would not make the night." "The only hope she had would be to go on the urgent transplant list. And to get her there, she would need to have a Berlin heart," Terry said, referencing the artificial heart which Bea ended up having. The little one ended up waiting 14 months in the hospital while she waited for a transplant, and Terry said the family had witnessed some tragic moments while there. "Within the space of a week, both the children either side [of Bea's bed] passed," Terry shared. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. He said that the moment Bea received a transplant was "incredible," but he acknowledged the heartbreaking decision one family had to make to ensure that Bea lived. "The reality is, we know what it meant to the other side so it's like living an endless torture," he recalled. "Every day wondering, 'Is this the day that we lose Bea? Is it her last day with us?' And enjoying every moment." "And at the same time, very conscious of what it means for her to come home, that if she does, her life from that moment, every breath, everything she goes on to do is because of somebody else," Terry — who had previously made the difficult decision, along with Cheryl, to donate their stillborn daughter's heart — added. Read the original article on People


Medscape
29 minutes ago
- Medscape
Rapid Review: Endometrial Cancer
In endometrial cancer, the majority of cases are diagnosed at an early stage, largely due to the hallmark symptom of postmenopausal bleeding. Despite relatively favorable survival rates when caught early — with a 5-year relative survival rate of approximately 95% for localized disease — disparities remain in detection, treatment access, and mortality. ctDNA testing has shown strong value as a noninvasive and highly sensitive method for detecting recurrence in endometrial cancer. ctDNA detects tumor-specific mutations in the bloodstream and is being actively evaluated to track cancer progression, detect early-stage cancers, and monitor therapeutic responses. ctDNA's role for detecting hormone receptor status and tumor histology has not been established for endometrial cancer, and it appears to not be correlated with myometrial invasion depth. Learn more about the presentation of endometrial cancer. In the past year, evidence has emerged which demonstrates that GLP-1 receptor agonists — medications originally approved for diabetes and obesity — reduce the risk for obesity-related cancers. A major research effort found that these drugs decreased cancer incidence, and further research found GLP-1 receptor agonists to be comparable to bariatric surgery for obesity-related cancer prevention. GLP-1 therapies now offer a less-invasive alternative to bariatric surgery. Research is ongoing to evaluate the use of GLP-1 medications as a potential therapeutic strategy for endometrial cancer. The other classes have not been shown to reduce risk or are not used in endometrial cancer management. Learn more about the differential diagnosis for endometrial cancer. Recent advances in molecular and genomic profiling have significantly refined the precision with which therapies can be selected for patients with endometrial cancer. These tools enable clinicians to pinpoint genetic and molecular characteristics that dictate tumor behavior and response to treatment, improving personalized treatment strategies and overall survival outcomes. Rather than uniformly applying treatments, clinicians have the ability to tailor therapies based on individual molecular profiles. Adjuvant therapy may still be warranted depending on the risk associated with the molecular/genomic subtypes identified, and best practice histopathology evaluation is still needed even when advanced profiling is done. Further research continues to expand the depth and breadth of genomic profiling, making it a crucial element of modern oncology practice. Learn more about the workup for endometrial cancer. The TCGA molecular classification divides endometrial cancers into four biologically distinct subtypes: POLE-ultramutated, MSI-H, copy number-low (endometrioid), and copy number-high (serous-like). These molecular profiles provide prognostic insights and increasingly guide therapeutic strategies beyond traditional histology and staging. For example, POLE-mutated tumors, despite high mutation burdens, have excellent outcomes and may not require aggressive adjuvant therapy. In contrast, copy number-high tumors are associated with poor prognosis and may benefit from more intensive treatment and HER2-targeted therapies. This classification is part of a shift toward personalized medicine in gynecologic oncology. Learn more about guidelines for endometrial cancer. Compared to traditional open surgery, MIS dramatically shortens hospital stays, decreases blood loss, and has fewer overall complications, although it does lengthen operation time. Furthermore, minimally invasive approaches maintain oncologic outcomes comparable to those of traditional open surgery, providing reassurance regarding their safety and efficacy. Because endometrial cancer patients often have obesity, MIS has the potential to reduce the risk for postoperative wound complications. It also is likely to decrease other postoperative morbidities by supporting faster recovery and earlier resumption of normal daily activities. Additionally, lymph node assessment may still be needed after MIS. Learn more about risk assessment in patients with endometrial cancer.